| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 54.061 | 53.984 | 53.850 | 54.081 | 53.809 | 53.786 | 54.498 | 54.687 | 54.816 | 54.859 |
| Total Income - EUR | 54.080 | 53.984 | 53.851 | 54.443 | 53.830 | 53.786 | 54.498 | 54.687 | 54.816 | 54.859 |
| Total Expenses - EUR | 9.022 | 17.071 | 17.109 | 17.045 | 17.701 | 18.328 | 17.382 | 14.087 | 12.282 | 16.250 |
| Gross Profit/Loss - EUR | 45.058 | 36.913 | 36.742 | 37.397 | 36.129 | 35.458 | 37.116 | 40.600 | 42.533 | 38.609 |
| Net Profit/Loss - EUR | 43.436 | 35.833 | 36.204 | 36.853 | 35.591 | 34.961 | 36.582 | 40.061 | 41.996 | 38.071 |
| Employees | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
Check the financial reports for the company - Pharmacon S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 44.961 | 44.492 | 41.733 | 83.614 | 79.775 | 76.120 | 72.336 | 70.458 | 83.693 | 80.664 |
| Current Assets | 18.245 | 11.112 | 18.101 | 17.035 | 20.503 | 20.313 | 24.373 | 32.008 | 33.360 | 32.428 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 1.889 | 11 | 49 | 49 |
| Cash | 18.245 | 11.112 | 18.101 | 17.035 | 20.503 | 20.313 | 22.484 | 31.997 | 33.310 | 32.379 |
| Shareholders Funds | 61.472 | 53.686 | 53.754 | 98.698 | 96.238 | 94.458 | 94.760 | 98.420 | 115.722 | 111.385 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 2.122 | 2.381 | 6.556 | 2.246 | 4.315 | 2.232 | 2.201 | 4.046 | 1.330 | 1.706 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Pharmacon S.r.l.